Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubamatamab With and Without Marlotamig in Advanced/Metastatic NSCLC
NCT07154290Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Jun 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ubamatamab, dalmitamig in non-small cell lung cancer (NSCLC), sponsored by Regeneron Pharmaceuticals. Started Mar 2026; status: recruiting.
02
Drugs
ubamatamabdalmitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07154290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07154290.